

according to GB/T 16483 and GB/T 17519

Olmesartan / Hydrochlorothiazide Formulation

Vers 3.8	sion	Revision Date: 2020/10/10		S Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07
1. Pi	RODUC	T AND COMPANY IDE	ENT	IFICATION	
	Product name		:	Olmesartan / Hyd	drochlorothiazide Formulation
	Manufa	acturer or supplier's d	letai	ls	
	Compa	ny	:	Organon & Co.	
	Address		:	30 Hudson Stree Jersey City, New	t, 33nd floor Jersey, U.S.A 07302
	Teleph	one	:	551-430-6000	
	Emerge	ency telephone number	:	215-631-6999	
	E-mail	address	:	EHSSTEWARD	⊉organon.com
	Recommended use of the chemical and restrictions on use				

: Pharmaceutical

2. HAZARDS IDENTIFICATION

Recommended use

Emergency Overview

Appearance Colour Odour	:	powder white to off-white No data available
May damage the unborn child. I posure.	Ma	y cause damage to organs through prolonged or repeated ex-
GHS Classification		
Reproductive toxicity	:	Category 1A
Specific target organ toxicity - repeated exposure	:	Category 2
GHS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360D May damage the unborn child. H373 May cause damage to organs through prolonged or re- peated exposure.
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read

according to GB/T 16483 and GB/T 17519



Olmesartan / Hydrochlorothiazide Formulation

3.8 2020/10/10 402497-00012 Date of first issue: 2016/01/07	Version 3.8	Revision Date: 2020/10/10	SDS Number: 402497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07	
---	----------------	------------------------------	-----------------------------	---	--

and understood. P260 Do not breathe dust. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Not classified based on available information.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Olmesartan	144689-63-4	>= 1 -< 10
Cellulose	9004-34-6	>= 1 -< 10
Hydrochlorothiazide	58-93-5	>= 1 -< 10

4. FIRST AID MEASURES

General advice	 In the case of accident or if you feel unwell, seek medica vice immediately. When symptoms persist or in all cases of doubt seek me advice. 	
If inhaled In case of skin contact	 If inhaled, remove to fresh air. Get medical attention. In case of contact, immediately flush skin with soap and of water. Remove contaminated clothing and shoes. Get medical attention. 	plenty

SAFETY DATA SHEET according to GB/T 16483 and GB/T 17519



Version 3.8	Revision Date: 2020/10/10		0S Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07				
	In case of eye contact If swallowed		 Wash clothing before reuse. Thoroughly clean shoes before reuse. If in eyes, rinse well with water. Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. 					
Most important symptoms and effects, both acute and delayed		:	May cause damage to organs through prolonged or repear exposure. Contact with dust can cause mechanical irritation or drying the skin.					
Prote	ection of first-aiders	:	 Dust contact with the eyes can lead to mechanical irritation First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively. 					
Note	es to physician	:						
5. FIREFIGHTING MEASURES								
Suita	Suitable extinguishing media		Water spray Alcohol-resistant Carbon dioxide (0 Dry chemical					
Unsi med	uitable extinguishing ia	:	None known.					
	Specific hazards during fire- fighting		concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. pustion products may be a hazard to health.				
Haza ucts	ardous combustion prod-	:	Carbon oxides Nitrogen oxides (Chlorine compou Sulphur oxides					
Spec ods	Specific extinguishing meth- ods		cumstances and Use water spray	measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do				
	cial protective equipment refighters	:	In the event of fire	e, wear self-contained breathing apparatus. tective equipment.				
6. ACCID	ENTAL RELEASE MEAS	SUF	RES					
tive	Personal precautions, protec- tive equipment and emer-		Follow safe hand	tective equipment. ling advice (see section 7) and personal pro-				

gency procedures		tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Revision Date:

Version



Date of last issue: 2020/03/23

Olmesartan / Hydrochlorothiazide Formulation

SDS Number:

Version Revision Date: 3.8 2020/10/10	SDS Number: 402497-00012	Date of first issue: 2020/03/23 Date of first issue: 2016/01/07
	Local authoritie cannot be cont	es should be advised if significant spillages ained.
Methods and materials for containment and cleaning up	tainer for dispersa Avoid dispersa with compress Dust deposits es, as these m leased into the Local or nation posal of this m employed in th mine which reg Sections 13 an	I of dust in the air (i.e., clearing dust surfaces
7. HANDLING AND STORAGE		
Handling Technical measures	causing an exp	y may accumulate and ignite suspended dust blosion. ate precautions, such as electrical grounding
Local/Total ventilation		or inert atmospheres. ntilation is unavailable, use with local exhaust
Advice on safe handling	: Do not get on s Do not breather Do not swallow Avoid contact w Wash skin thou Handle in accor practice, based sessment Keep containe Minimize dust Keep containe Keep away fro Take precautio Do not eat, driv	Ι.
Avoidance of contact	: Oxidizing ager	ıts
Storage		
Conditions for safe storage Materials to avoid	 Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulation Do not store with the following product types: Strong oxidizing agents 	
Packaging material	: Unsuitable ma	terial: None known.

according to GB/T 16483 and GB/T 17519



Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
3.8	2020/10/10	402497-00012	Date of first issue: 2016/01/07

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Olmesartan	144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Cellulose	9004-34-6	PC-TWA	10 mg/m3	CN OEL
		TWA	10 mg/m3	ACGIH
Hydrochlorothiazide	58-93-5	TWA	100 µg/m3 (OEB 2)	Internal

Engineering measures

 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.


Personal protective equipment

Respiratory protection :		If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.
Filter type Eye/face protection		Particulates type Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection :	•	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hand protection		
Material :	:	Chemical-resistant gloves
Remarks Hygiene measures		Consider double gloving. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work- ing place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,





Version 3.8	Revision Date: 2020/10/10		S Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07
			industrial hygiene use of administrat	monitoring, medical surveillance and the tive controls.
9. PHYSIC	CAL AND CHEMICAL PI	ROP	ERTIES	
Appe	arance	:	powder	
Colou	ır	:	white to off-white	
Odou	r	:	No data available	9
Odou	r Threshold	:	No data available	9
pН		:	No data available	9
Meltir	ng point/freezing point	:	No data available	9
Initial range	boiling point and boiling	:	No data available	2
Flash	point	:	Not applicable	
Evap	oration rate	:	Not applicable	
Flam	mability (solid, gas)	:	May form explosi dling or other me	ive dust-air mixture during processing, han- ans.
Flam	mability (liquids)	:	No data available	9
	r explosion limit / Upper nability limit	:	No data available	9
	r explosion limit / Lower nability limit	:	No data available	9
Vapo	ur pressure	:	Not applicable	
Relat	ive vapour density	:	Not applicable	
Relat	ive density	:	No data available	9
Dens	ity	:	No data available	9
	bility(ies) ater solubility	:	No data available	9
	ion coefficient: n-	:	Not applicable	
	ol/water ignition temperature	:	No data available	9
Deco	mposition temperature	:	No data available	9
Visco Vi	sity scosity, kinematic	:	Not applicable	





Version 3.8	Revision Date: 2020/10/10		S Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07			
Exp	Explosive properties		Not explosive				
Oxi	dizing properties	:	The substance o	r mixture is not classified as oxidizing.			
Mol	ecular weight	:	Not applicable				
Par	ticle size	:	No data available	e			
10. STA	BILITY AND REACTIVITY	,					
Che Pos	Reactivity Chemical stability Possibility of hazardous reac- tions		Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.				
Inco Haz	nditions to avoid ompatible materials cardous decomposition ducts	 Heat, flames and sparks. Avoid dust formation. Oxidizing agents No hazardous decomposition products are known. 					
11. TOX	ICOLOGICAL INFORMAT	ION					
Exp	osure routes	:	Inhalation Skin contact Ingestion Eye contact				
	ite toxicity classified based on availa	ble i					
Pro	duct:						
Αςι	te oral toxicity	:	Acute toxicity esti Method: Calculati	mate: > 5,000 mg/kg on method			
<u>Co</u>	nponents:						
	nesartan:			00			
ACL	ite oral toxicity	:	LD50 (Rat): > 2,0				
			LD50 (Mouse): >				
			LD50 (Dog): > 1,5	500 mg/kg			
Αςι	te inhalation toxicity	:	Remarks: No data	a available			
Αςι	te dermal toxicity	:	Remarks: No data	a available			
	lulose: ite oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg			



according to GB/T 16483 and GB/T 17519

Version 3.8	Revision Date: 2020/10/10		9S Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07		
Acu	te inhalation toxicity	:	LC50 (Rat): > 5.8 Exposure time: 4 Test atmosphere:	h		
Acu	te dermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg		
Нус	drochlorothiazide:					
Acu	te oral toxicity	:	LD50 (Rat): > 2,7	50 mg/kg		
			LD50 (Mouse): > 2	2,830 mg/kg		
	te toxicity (other routes of ninistration)	:	LD50 (Rat): 990 n Application Route			
			LD50 (Mouse): 59 Application Route			
-	n corrosion/irritation classified based on availa	ble	information.			
<u>Cor</u>	nponents:					
	nesartan:					
Rer	narks	:	No data available			
Нус	drochlorothiazide:					
Spe Res	ecies sult	:	Rabbit No skin irritation			
	ious eye damage/eye irri					
	classified based on availa nponents:	bie	information.			
	nesartan:					
		:	Rabbit			
Res	sult	:	Moderate eye irrit	ation		
Met	hod	:	Draize Test			
Нус	Irochlorothiazide:					
Spe Res	ecies sult	:	Rabbit Mild eye irritation			
Res	spiratory or skin sensitis	atic	'n			
Ski	n sensitisation					
Not	classified based on availa	ble	information.			
	piratory sensitisation					
Not	classified based on availa	ble	information.			





Ver 3.8	sion	Revision Date: 2020/10/10		DS Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07
	Comp	onents:			
	Olmes	artan:			
	Exposi Remar	ure routes ks	:	Skin contact No data available	
		cell mutagenicity assified based on avail	able	information.	
	Comp	onents:			
	Olmes	artan:			
	Genoto	oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
				Test Type: Mutag Result: negative	enicity (in vitro mammalian cytogenetic test)
					nosome aberration test in vitro nese hamster lung cells
				Test Type: Mouse Result: negative	e Lymphoma
	Genoto	oxicity in vivo	:	Test Type: Micror Species: Mouse Cell type: Bone m Application Route Result: negative	arrow
	Germ o Assess	cell mutagenicity - sment	:	Weight of evidend cell mutagen.	ce does not support classification as a germ
	Cellulo	ose:			
		oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
				Test Type: In vitro Result: negative	o mammalian cell gene mutation test
	Genoto	oxicity in vivo	:	Test Type: Mamn cytogenetic assay Species: Mouse Application Route Result: negative	
	Hydro	chlorothiazide:			
	-	oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
				Test Type: Chrom	nosomal aberration

according to GB/T 16483 and GB/T 17519



ersion B	Revision Date: 2020/10/10	SDS Number: 402497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07
		Test system: C Result: negativ	Chinese hamster ovary cells ve
			ter chromatid exchange assay Chinese hamster ovary cells e
		Test Type: in v Test system: n Result: positive	nouse lymphoma cells
Genot	toxicity in vivo	: Test Type: Ch Species: Chine Cell type: Bone Result: negativ	e marrow
		Test Type: in N Species: Mous Cell type: Bon Result: negativ	se e marrow
Germ	cell mutagenicity -		ence does not support classification as a germ
	ssment	cell mutagen.	
Asses Carci Not cl	ssment nogenicity assified based on av	-	
Asses Carci Not cl <u>Comr</u>	nogenicity assified based on av ponents:	-	
Asses Carci Not cl <u>Comp</u> Olme	nogenicity assified based on av ponents: sartan:	ailable information.	
Asses Carci Not cl <u>Comp</u> Olme Speci	nogenicity assified based on av ponents: sartan:	-	
Asses Carci Not cl Comp Olme Speci Applic Expos	assment nogenicity assified based on av <u>conents:</u> sartan: es cation Route sure time	ailable information. : Rat : Oral : 2 Years	
Asses Carci Not cl <u>Comp</u> Olme Speci Applic	assment nogenicity assified based on av <u>conents:</u> sartan: es cation Route sure time	ailable information. : Rat : Oral	
Asses Carci Not cl Comp Olme Speci Applic Expos	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t	ailable information. : Rat : Oral : 2 Years	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t es cation Route	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos	assment nogenicity assified based on av <u>conents:</u> sartan: es cation Route sure time t es cation Route sure time	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 0ral : 6 Months	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic	assment nogenicity assified based on av <u>conents:</u> sartan: es cation Route sure time t es cation Route sure time	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t es cation Route sure time t	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 0ral : 6 Months	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos Resul	assment nogenicity assified based on av <u>conents:</u> sartan: es cation Route sure time t es cation Route sure time t lose:	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 0ral : 6 Months	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos Resul Cellul Speci Applic	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t lose: es cation Route	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 6 Months : negative : negative : Rat : Ingestion	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos Resul Cellul Speci Applic Expos	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t es cation Route sure time t lose: es cation Route sure time t	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 6 Months : negative : Rat : Ingestion : 72 weeks	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos Resul Cellul Speci Applic	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t es cation Route sure time t lose: es cation Route sure time t	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 6 Months : negative : negative : Rat : Ingestion	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t lose: es cation Route sure time t t	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 6 Months : negative : Rat : Ingestion : 72 weeks	
Asses Carci Not cl Comp Olme Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul	assment nogenicity assified based on av ponents: sartan: es cation Route sure time t lose: es cation Route sure time t boshlorothiazide:	ailable information. : Rat : Oral : 2 Years : negative : Mouse : Oral : 6 Months : negative : Rat : Ingestion : 72 weeks : negative	
Asses Carci Not cl Come Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul	assment nogenicity assified based on av <u>ponents:</u> sartan: es cation Route sure time t lose: es cation Route sure time t chlorothiazide: es cation Route	ailable information.	
Asses Carci Not cl Come Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul Speci Applic Expos Resul	assment nogenicity assified based on av ponents: sartan: es cation Route sure time t lose: es cation Route sure time t bochlorothiazide: es cation Route sure time t	ailable information.	

according to GB/T 16483 and GB/T 17519



Vers 3.8	ion	Revision Date: 2020/10/10		DS Number:Date of last issue: 2020/03/2302497-00012Date of first issue: 2016/01/07	
	Species Application Route Exposure time Result		:	Mouse, male Oral 2 Years equivocal	
	Species Application Route Exposure time Result		:	Rat, male and fem Oral 2 Years negative	nale
	May da	luctive toxicity mage the unborn child			
	<u>Compo</u>				
	Olmesa Effects	artan: on fertility	:	Test Type: Fertility Species: Rat Application Route Fertility: NOAEL: Result: No effects	: Oral 1,000 mg/kg body weight
	Effects ment	on foetal develop-	:	Test Type: Develo Species: Rat Application Route Dose: 1000 millign Result: No teratog	: Oral am per kilogram
				Test Type: Develo Species: Rabbit Application Route Dose: 1 milligram Result: No teratog	oral per kilogram
				Symptoms: Malfor weight	
	Reprod sessme	uctive toxicity - As- ent	:	Positive evidence human epidemiolo	of adverse effects on development from ogical studies.
	Cellulo	se:			
		on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study
	Effects ment	on foetal develop-	:	Test Type: Fertility Species: Rat	/early embryonic development



according to GB/T 16483 and GB/T 17519

Olmesartan / Hydrochlorothiazide Formulation

Version 3.8	Revision Date: 2020/10/10	SDS Number: 402497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07
		Application Result: negat	oute: Ingestion ive
Hydro	ochlorothiazide:		
-	Effects on fertility :		ertility male and female oute: oral (feed) EL: 4 mg/kg body weight s on fertility
		Application R	ise, male and female oute: oral (feed) EL: 100 mg/kg body weight
Effect ment	s on foetal develop-		ISE
	- single exposure assified based on avai	lable information.	
	- repeated exposure cause damage to orgar		d or repeated exposure.

Components:

Hydrochlorothiazide:


Target Organs	:	Kidney, Parathyroid gland
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

Repeated dose toxicity

Components:

Olmesartan:

Species	: Rat	
NOAEL	: 2,000 mg/kg	
Application Route	: Oral	
Exposure time	: 24 Months	
Remarks	: No significant	adverse effects were reported





Olmesartan / Hydrochlorothiazide Formulation

Version 3.8	Revision Date: 2020/10/10	SDS Number: 402497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07			
Spec NOA Appli		: Rat : >= 9,000 mg/kg : Ingestion : 90 Days				
Hydr	ochlorothiazide:					
Expo		: Rat, male and : 10 mg/kg : Oral : 2 yr : Kidney, Parath				
	EL cation Route sure time	: Mouse, male a : 300 - 550 mg/l : Oral : 2 yr : No significant				
Spec	ies	: Dog				
Expo	cation Route sure time et Organs	: 50 - 200 mg/kg : Oral : 9 Months : Parathyroid gla				
•	ration toxicity classified based on ava	ilable information.				

Components:

Hydrochlorothiazide:

No aspiration toxicity classification

Experience with human exposure

Components:

Olmesartan:

Eye contact	:	Symptoms: Eye irritation
Ingestion	:	Symptoms: hypotension
-		Remarks: May cause harm to the unborn child.
		Based on Human Evidence
Hydrochlorothiazide:		

Eye contact	: Symptoms: Eye irritation
Ingestion	: Symptoms: Dizziness, Headache, Fatigue, Nausea, Ab-
-	dominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

according to GB/T 16483 and GB/T 17519



Olmesartan / Hydrochlorothiazide Formulation

ersion 8	Revision Date: 2020/10/10		S Number: 2497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07
2. ECOL	OGICAL INFORMATION	N		
Ecoto	oxicity			
<u>Com</u>	oonents:			
Cellu	lose:			
Toxic	ity to fish	:	Exposure time:	atipes (Japanese medaka)): > 100 mg/l 48 h d on data from similar materials
Hydro	ochlorothiazide:			
Toxic	ity to fish	:	LC50 (Pimepha Exposure time:	lles promelas (fathead minnow)): > 500 mg/l 96 h
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia Exposure time:	magna (Water flea)): > 500 mg/l 48 h
Persi	stence and degradabil	ity		
<u>Com</u>	ponents:			
Cellu	lose:			
Biode	gradability	:	Result: Readily	biodegradable.
Hydro	ochlorothiazide:			
-	ity in water	:	Hydrolysis: 46.2	2 %(96 h)
	ccumulative potential			
	lity in soil			
	ata available			
	r adverse effects ata available			

Waste from residues Contaminated packaging	 Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. 	

14. TRANSPORT INFORMATION

International Regulations

UNRTDG



according to GB/T 16483 and GB/T 17519

Olmesartan / Hydrochlorothiazide Formulation

Version 3.8	Revision Date: 2020/10/10	SDS Number: 402497-00012	Date of last issue: 2020/03/23 Date of first issue: 2016/01/07				
Not r	Not regulated as a dangerous good						
	IATA-DGR Not regulated as a dangerous good						
	IMDG-Code Not regulated as a dangerous good						
	Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.						
Natio	National Regulations						
	GB 6944/12268 Not regulated as a dangerous good						
•	Special precautions for user Not applicable						
15. REGULATORY INFORMATION							
National regulatory information Law on the Prevention and Control of Occupational Diseases							
The AICS	• •	roduct are reported : not determined	in the following inventories:				

	-	
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Further information

i ui u					
	oile the Safety Data	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/		
Date	format	:	yyyy/mm/dd		
Full text of other abbreviations					
ACG CN C		:	USA. ACGIH Threshold Limit Values (TLV)		
		•	Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.		
	IH / TWA		8-hour, time-weighted average		
	DEL / PC-TWA	•	Permissible concentration - time weighted average		

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with



Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
3.8	2020/10/10	402497-00012	Date of first issue: 2016/01/07

x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN